SAFC Pharma Expands its UK Pharmorphix Facility
News Feb 16, 2007
SAFC, a member of the Sigma-Aldrich Group has announced that it has completed the initial phase of a two-stage expansion at its SAFC Pharmorphix™ research facility in Cambridge, U.K., for its SAFC Pharma business.
Completion of a 2,500 sq. ft. laboratory extension will be followed by additional investment in spring 2007 as part of a $600,000 expansion program.
SAFC Pharmorphix is one of a few organizations specializing in solid form characterization and research. These services focus on understanding and modifying the physical properties of Active Pharmaceutical Ingredients (APIs) to ensure patient benefit, optimize product development and protect intellectual property.
Services include polymorph investigation, salt selection, physiochemical property determinations, pre-formulation profiling, co-crystallization, classical chiral resolution and crystallization studies.
The expanded laboratory will support expected growth in addition to developing leading-edge science and analytical techniques. In the second quarter of 2007, SAFC Pharmorphix expects to introduce additional state-of-the-art X-ray crystallography equipment into the lab.
Last November, SAFC Pharma announced plans to expand Pharmorphix’ capabilities into the U.S. with a new laboratory at their flagship high potency active pharmaceutical ingredients facility in Madison, Wisconsin. The new U.S. lab is expected to be operational in spring 2007.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019